SUBSCRIBE TO OUR FREE NEWSLETTER
Daily news & progressive opinion—funded by the people, not the corporations—delivered straight to your inbox.
5
#000000
#FFFFFF
5
#000000
#FFFFFF
US Doctor Group Demands Price Controls for Out-of-Control Drug Industry
American College of Physicians publishes policy paper on getting skyrocketing drug prices under control
Mar 29, 2016
The American College of Physicians (ACP), a group of 143,000 internal medicine doctors, on Tuesday published a position paper calling on the government to do more to regulate the skyrocketing costs of pharmaceutical drugs.
The article, written by the ACP's Health and Public Policy Committee and published in the Annals of Internal Medicine, notes that the U.S. is one of the only economically advanced countries in the world that does not have any government regulation of drug prices.
"In the United States we pay comparatively much more for prescription drugs than other countries, an increasing concern for all Americans," said ACP president Dr. Wayne J. Riley. "The impact of these rising costs can be very detrimental to patients, causing them to forgo filling important prescriptions or not taking drugs on the schedule that they are prescribed."
The ACP made seven recommendations to help slow down and maintain the price of medicine, including:
- Transparency in the pricing, cost, and comparative value of all pharmaceutical products;
- Allowing price negotiation by Medicare and other publicly-funded health programs, consideration of reimporting drugs manufactured in the U.S., and increasing competition for sole-source drugs;
- Ensuring that patient cost-sharing is not set at a level that imposes a "substantial economic barrier" to patients.
As NPR reports, the ACP also called for "drugmakers to disclose the actual research and production costs of developing and manufacturing each drug, and to disclose the prices paid for drugs--including discounts and rebates--that take advantage of basic research funded by the government, such as the National Institutes of Health and the Department of Veterans Affairs."
The ACP writes in its paper:
Pricing (the base price of a drug before negotiations, rebates, and discounts), cost (the actual dollar amount paid by patients, health plans, or the government for a drug), and value (the benefit of a drug relative to its cost) are intertwined, and as policymakers look for solutions, they must consider all 3 issues in order to understand the broader implications of policies or regulatory action.
The article comes amid several high-profile cases of life-saving drugs reaching out-of-control costs.
Notorious Turing Pharmaceuticals CEO Martin Shkreli, for example, increased the price of the malaria medication Daraprim from $12.50 to $750 a pill in September. He was later indicted for securities fraud.
In a Kaiser Family Foundation survey conducted last August, 70 percent of respondents said they felt that drug prices were too high and pharmaceutical companies were only interested in making a profit.
"We continue to pay more and more for drugs, making it harder and harder for patients to afford critical prescriptions. This situation must change," Riley said on Tuesday. "A prescription drug can only be as effective as a patient's ability to access it and adhere to the medication as prescribed. Year after year of rising costs is clearly a burden for many patients that ultimately impacts their health and quality of life."
An Urgent Message From Our Co-Founder
Dear Common Dreams reader, It’s been nearly 30 years since I co-founded Common Dreams with my late wife, Lina Newhouser. We had the radical notion that journalism should serve the public good, not corporate profits. It was clear to us from the outset what it would take to build such a project. No paid advertisements. No corporate sponsors. No millionaire publisher telling us what to think or do. Many people said we wouldn't last a year, but we proved those doubters wrong. Together with a tremendous team of journalists and dedicated staff, we built an independent media outlet free from the constraints of profits and corporate control. Our mission has always been simple: To inform. To inspire. To ignite change for the common good. Building Common Dreams was not easy. Our survival was never guaranteed. When you take on the most powerful forces—Wall Street greed, fossil fuel industry destruction, Big Tech lobbyists, and uber-rich oligarchs who have spent billions upon billions rigging the economy and democracy in their favor—the only bulwark you have is supporters who believe in your work. But here’s the urgent message from me today. It's never been this bad out there. And it's never been this hard to keep us going. At the very moment Common Dreams is most needed, the threats we face are intensifying. We need your support now more than ever. We don't accept corporate advertising and never will. We don't have a paywall because we don't think people should be blocked from critical news based on their ability to pay. Everything we do is funded by the donations of readers like you. When everyone does the little they can afford, we are strong. But if that support retreats or dries up, so do we. Will you donate now to make sure Common Dreams not only survives but thrives? —Craig Brown, Co-founder |
Our work is licensed under Creative Commons (CC BY-NC-ND 3.0). Feel free to republish and share widely.
Nadia Prupis
Nadia Prupis is a former Common Dreams staff writer. She wrote on media policy for Truthout.org and has been published in New America Media and AlterNet. She graduated from UC Santa Barbara with a BA in English in 2008.
The American College of Physicians (ACP), a group of 143,000 internal medicine doctors, on Tuesday published a position paper calling on the government to do more to regulate the skyrocketing costs of pharmaceutical drugs.
The article, written by the ACP's Health and Public Policy Committee and published in the Annals of Internal Medicine, notes that the U.S. is one of the only economically advanced countries in the world that does not have any government regulation of drug prices.
"In the United States we pay comparatively much more for prescription drugs than other countries, an increasing concern for all Americans," said ACP president Dr. Wayne J. Riley. "The impact of these rising costs can be very detrimental to patients, causing them to forgo filling important prescriptions or not taking drugs on the schedule that they are prescribed."
The ACP made seven recommendations to help slow down and maintain the price of medicine, including:
- Transparency in the pricing, cost, and comparative value of all pharmaceutical products;
- Allowing price negotiation by Medicare and other publicly-funded health programs, consideration of reimporting drugs manufactured in the U.S., and increasing competition for sole-source drugs;
- Ensuring that patient cost-sharing is not set at a level that imposes a "substantial economic barrier" to patients.
As NPR reports, the ACP also called for "drugmakers to disclose the actual research and production costs of developing and manufacturing each drug, and to disclose the prices paid for drugs--including discounts and rebates--that take advantage of basic research funded by the government, such as the National Institutes of Health and the Department of Veterans Affairs."
The ACP writes in its paper:
Pricing (the base price of a drug before negotiations, rebates, and discounts), cost (the actual dollar amount paid by patients, health plans, or the government for a drug), and value (the benefit of a drug relative to its cost) are intertwined, and as policymakers look for solutions, they must consider all 3 issues in order to understand the broader implications of policies or regulatory action.
The article comes amid several high-profile cases of life-saving drugs reaching out-of-control costs.
Notorious Turing Pharmaceuticals CEO Martin Shkreli, for example, increased the price of the malaria medication Daraprim from $12.50 to $750 a pill in September. He was later indicted for securities fraud.
In a Kaiser Family Foundation survey conducted last August, 70 percent of respondents said they felt that drug prices were too high and pharmaceutical companies were only interested in making a profit.
"We continue to pay more and more for drugs, making it harder and harder for patients to afford critical prescriptions. This situation must change," Riley said on Tuesday. "A prescription drug can only be as effective as a patient's ability to access it and adhere to the medication as prescribed. Year after year of rising costs is clearly a burden for many patients that ultimately impacts their health and quality of life."
Nadia Prupis
Nadia Prupis is a former Common Dreams staff writer. She wrote on media policy for Truthout.org and has been published in New America Media and AlterNet. She graduated from UC Santa Barbara with a BA in English in 2008.
The American College of Physicians (ACP), a group of 143,000 internal medicine doctors, on Tuesday published a position paper calling on the government to do more to regulate the skyrocketing costs of pharmaceutical drugs.
The article, written by the ACP's Health and Public Policy Committee and published in the Annals of Internal Medicine, notes that the U.S. is one of the only economically advanced countries in the world that does not have any government regulation of drug prices.
"In the United States we pay comparatively much more for prescription drugs than other countries, an increasing concern for all Americans," said ACP president Dr. Wayne J. Riley. "The impact of these rising costs can be very detrimental to patients, causing them to forgo filling important prescriptions or not taking drugs on the schedule that they are prescribed."
The ACP made seven recommendations to help slow down and maintain the price of medicine, including:
- Transparency in the pricing, cost, and comparative value of all pharmaceutical products;
- Allowing price negotiation by Medicare and other publicly-funded health programs, consideration of reimporting drugs manufactured in the U.S., and increasing competition for sole-source drugs;
- Ensuring that patient cost-sharing is not set at a level that imposes a "substantial economic barrier" to patients.
As NPR reports, the ACP also called for "drugmakers to disclose the actual research and production costs of developing and manufacturing each drug, and to disclose the prices paid for drugs--including discounts and rebates--that take advantage of basic research funded by the government, such as the National Institutes of Health and the Department of Veterans Affairs."
The ACP writes in its paper:
Pricing (the base price of a drug before negotiations, rebates, and discounts), cost (the actual dollar amount paid by patients, health plans, or the government for a drug), and value (the benefit of a drug relative to its cost) are intertwined, and as policymakers look for solutions, they must consider all 3 issues in order to understand the broader implications of policies or regulatory action.
The article comes amid several high-profile cases of life-saving drugs reaching out-of-control costs.
Notorious Turing Pharmaceuticals CEO Martin Shkreli, for example, increased the price of the malaria medication Daraprim from $12.50 to $750 a pill in September. He was later indicted for securities fraud.
In a Kaiser Family Foundation survey conducted last August, 70 percent of respondents said they felt that drug prices were too high and pharmaceutical companies were only interested in making a profit.
"We continue to pay more and more for drugs, making it harder and harder for patients to afford critical prescriptions. This situation must change," Riley said on Tuesday. "A prescription drug can only be as effective as a patient's ability to access it and adhere to the medication as prescribed. Year after year of rising costs is clearly a burden for many patients that ultimately impacts their health and quality of life."
We've had enough. The 1% own and operate the corporate media. They are doing everything they can to defend the status quo, squash dissent and protect the wealthy and the powerful. The Common Dreams media model is different. We cover the news that matters to the 99%. Our mission? To inform. To inspire. To ignite change for the common good. How? Nonprofit. Independent. Reader-supported. Free to read. Free to republish. Free to share. With no advertising. No paywalls. No selling of your data. Thousands of small donations fund our newsroom and allow us to continue publishing. Can you chip in? We can't do it without you. Thank you.